Research and development daily Novar3 RNAi Innovation Therapy was approved for clinical practice in China today

2020.09.11 Research and Development NEWS Challenge GSK, Sanofi! AstraZeneca Fasenra treatment of nasal pneumoconiosis phase III clinical results are positive, Sanofi long-acting coagulation factor replacement therapy clinical results are positive, can treat asthma and slow-blocking lung GSK triple therapy approved by the FDA ... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original) "Drug Research and Development" Takeda Ninlaro multiple myeloma clinical failure 9, Takeda announced NINLARO™ (ixazomib, Isazzomi) combined to treat newly diagnosed, non-compliant patients with multiple myeloma phase 3 clinical study TOURMALINE-MM2 results.
study found that the mid-progressive survival of patients increased by only 13.5 months when NINLARO was added to the combination of lanadoamine and dexamisun compared to placebo.
test did not reach the statistically significant threshold or the main endpoint of PFS.
challenge GSK, Sanofi! AstraZeneone's Phase III clinical results for nasal polyps were positive on Thursday, and AstraZeneone said that in a Phase 3 clinical trial, Fasenra's use in combination with standard steroids significantly reduced the size of nasal polyps and the severity of nasal congestion in patients with chronic sinusitis combined with nasal polyps (CRSwNP).
the success of this trial has once again intensified the competition between Fasenra and GSK's Nucala and Sanofi/Regenerative Dupixent.
latest data on the treatment of the anti-inflammatory drug Enspryng (satralizumab) for the treatment of optic neurospinalitis spectrum disorder (NMOSD) was released by Roche at the 8th ACTRIMS-ECTRIMS Joint Conference MSVirtual2020.
results showed that Enspryng significantly reduced the severity and risk of recurrence of NMOSD and the recurrence severity of the Sakura Star Phase 3 study (SakuraSky) double-blind period.
addition, aggregated data from the SAkura Open Label Extension (OLE) study supports the ongoing effects of long-term use of Enspryng to reduce the risk of recurrence.
Sanofi Long-Acting Coagulation Factor Alternative Therapy Clinical Results Positive Today, Sanofi announced that the company's innovative coagulation factor VIII alternative therapy BIVV001 (rFVIIIFc-VWF-XTEN), developed in collaboration with Sobi, has obtained positive results in a Phase 1/2a clinical trial.
test results show that BIVV001 can increase half-life by 3-4 times compared to traditional coagulation factor VIII (FVIII) alternative therapies.
Drug Approval: The FDA approved GSK and Innoviva for the simultaneous treatment of asthma and ADHD GSK triple therapy, and the FDA has approved Trelegy Ellipta (Hydrantikasson/Ume ammonium/Virantero, FF/UMEC/VI) extended adaptation for maintenance treatment for asthma patients over 18 years of age.
Gan Li Pharmaceutical CDK4/6 inhibitor was qualified by the FDA orphan drug to treat malignant glioma 10, Gan Li Pharmaceuticals announced that the FDA awarded its cell cycle protein-dependent kinase 4/6 (CDK4/6) inhibitor GLR2007 orphan drug eligibility for the treatment of malignant glioma including glioblastoma (GBM).
Johnson and Johnson submitted a new adaptation application for Darzalex suppositive injections on the 10th, Janssen announced that it has submitted to the FDA a license application for a supplemental biologics for Darzalex Faspro injections for the treatment of patients with light-chain amyloid degeneration.
Beijing Fuyuan "Omeshatan ester hydrochlorochlorine tablets" was approved for listing on the 11th, Beijing Fuyuan (formerly Beijing Wansheng Pharmaceuticals) 4 classes of generic drugs "Omeshatan esters hydrochlorochloride tablets" approved by the State Bureau for listing and as if through consistent evaluation, became the second domestic generic drugs listed in the variety.
is approved in China for the first-line maintenance treatment of ovarian cancer in the whole population 10, and then Ding Pharmaceuticals announced that NMPA has approved Cyle (Nirapali) supplementary new drug market application for advanced epitheliotic ovarian cancer, fallopian tube cancer or primary peritoneal cancer adult patients with first-line platinum-containing chemotherapy to achieve full or partial remission maintenance treatment.
Novartis submitted a clinically implied license for a new class 1 drug, inclisiran, with the latest clinical CDE approval in China today.
Zhengda Qing "Shaglitin tablets" was approved the second domestic 11th, Zhengtian Qing 4 classes of generic drug Shagritin tablets approved by the State Drug Administration listed, and as through the consistent evaluation, for the variety of domestic second imitation.
Fangsheng Pharmaceutical "Yi fold wheat cloth tablets" was approved for listing on the 11th, Hunan Fangsheng Pharmaceuticals 4 classes of generic drugs yi folding wheat cloth tablets listed application was approved by the State Drug Administration, becoming the first domestic imitation.